Oxolife, a biotech company specializing in improving live birth rates through enhanced embryo implantation in women undergoing assisted reproductive technology (ART) fertility treatment, proudly announces that its Chief Executive Officer, Agnès Arbat, has been honored with the prestigious EU Women Innovators Prize at the European Innovation Council (EIC) Summit held in Brussels, Belgium, on April 3, 2025.
This esteemed award, which includes a €100,000 prize, is dedicated to women founders and co-founders from the EU and Horizon Europe-associated countries who have successfully established innovative companies that have made significant market impacts. Agnès Arbat expressed her deep gratitude for this recognition, emphasizing the importance of advancing fertility treatments, an area of personal significance to her, and acknowledging the dedicated team at Oxolife, along with their advisors, investors, and supporters.
Agnès Arbat, with a rich background in the pharmaceutical industry spanning over two decades, has been pivotal in leading the clinical development and management of Oxolife since its inception in 2013. Her previous roles at Bayer and Organon showcased her expertise in women’s health, culminating in her current work on Oxolife’s lead candidate, OXO-001, a groundbreaking non-hormonal drug designed to enhance embryo implantation directly within the endometrium, offering promising results for infertile women undergoing IVF or ICSI.
Oxolife’s innovative approach with OXO-001 has already completed successful Phase 2 studies for enhancing embryo implantation and is poised to enter Phase 2 trials for a secondary indication focusing on Polycystic Ovary Syndrome (PCOS), demonstrating potential in restoring ovulation and boosting fertility. The company’s dedication to female fertility is underscored by its commitment to addressing critical challenges in reproductive medicine and providing effective solutions to improve pregnancy success rates.
The increasing global infertility market, growing at a rate of 4.5% annually due to various lifestyle factors, highlights the crucial need for advanced fertility treatments. With approximately 76 million affected women annually and a projected market value of $45.4 billion by 2029, Oxolife’s strategic focus on female fertility positions it as a key player in addressing the escalating decline in fertility rates worldwide. The company is actively seeking funding to expedite the development of OXO-001 and exploring potential partnerships to accelerate the delivery of its benefits to patients in need.
The European Prize for Women Innovators, managed by the European Innovation Council and SMEs Executive Agency (EISMEA) and the European Institute for Innovation & Technology (EIT), celebrates the pivotal role of women in driving transformative change and fostering innovation-driven growth within the EU. Recognizing over 30 women innovators and entrepreneurs since 2023, the prize serves as a platform to showcase female leadership, break barriers, and reshape the narrative surrounding women’s contributions to the innovation landscape.
Key Takeaways:
– Agnès Arbat, CEO of Oxolife, was awarded the EU Women Innovators Prize for her impactful work in advancing fertility treatments.
– Oxolife’s lead candidate, OXO-001, is a pioneering non-hormonal drug aimed at enhancing embryo implantation and improving pregnancy success rates.
– The global infertility market’s continuous growth underscores the importance of innovative solutions like OXO-001 in addressing fertility challenges.
– The European Prize for Women Innovators recognizes and celebrates women’s significant contributions to driving innovation and transformative change in the EU.
Tags: biotech
Read more on finanznachrichten.de